Login to Your Account



Clinic Roundup


Friday, June 14, 2013
• Immunomedics Inc., of Morris Plains, N.J., said UCB SA, of Brussels, Belgium, reported new data from a Phase IIb open-label extension study of epratuzumab for systemic lupus erythematosus showing no new safety or tolerability signals, plus reduction in disease activity maintained over two years. Secondary outcome data also showed that compared to baseline values, treatment for two years with epratuzumab was associated in lower corticosteroid use.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription